MedTrace Logo

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

NCT00313391 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-09-25

No results posted yet for this study

Summary

The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.

Conditions

Interventions

DRUG

Risperdal Consta

Sponsors & Collaborators

  • Janssen, L.P. - Investigator Initiated Studies Program

    collaborator UNKNOWN

  • Emory University

    lead OTHER

Principal Investigators

  • Dragana Bugarski-Kirola, MD · Emory University

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313391 on ClinicalTrials.gov